Research output

Research output per year 2011 2018 2020 2022 2023 2024

• 80 Article
• 54 Letter
• 3 Comment/debate
• 1 Editorial
• 2 More
  • 1 Short survey
  • 1 Review article

Research output per year

Research output per year

Search results

• 2024

  Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

  Tefferi, A., Pardanani, A., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M. R., Ketterling, R. P., Reichard, K. K. & Gangat, N., Dec 2024, In: Blood cancer journal. 14, 1, 51.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

  Johnson, I. M., Karrar, O., Rana, M., Iftikhar, M., Chen, S., McCullough, K., Saliba, A. N., Al-Kali, A., Alkhateeb, H., Begna, K., Litzow, M., Hogan, W. J., Shah, M., Patnaik, M. M., Pardanani, A., Hermann, J., Tefferi, A. & Gangat, N., 2024, (Accepted/In press) In: British journal of haematology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Non-ST Elevated Myocardial Infarction 41%
  • Pericarditis 39%
  • Cardiomyopathies 30%

• Chronic Myeloid Leukemia, Version 2.2024

  Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., DeAngelo, D. J., Drazer, M., Maness, L., Metheny, L., Mohan, S., Moore, J. O., Oehler, V., Pratz, K., Pusic, I., Rose, M. G., & 13 othersShomali, W., Douglas Smith, B., Styler, M., Talpaz, M., Tanaka, T. N., Tantravahi, S., Thompson, J., Tsai, S., Vaughn, J., Welborn, J., Yang, D. T., Sundar, H. & Gregory, K., Feb 2024, In: JNCCN Journal of the National Comprehensive Cancer Network. 22, 1, p. 43-69 27 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Leukemia, Myeloid, Chronic Phase 97%
  • Practice Guidelines 89%
  • Protein-Tyrosine Kinases 64%
  • Blast Crisis 64%

• Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant

  Begna, K. H., Abdallah, N. H., Janania-Martinez, M., Mangaonkar, A. A., Rangan, A., Herrick, J. L. & Gangat, N., Feb 2024, In: Haematologica. 109, 2, p. 689-692 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases

  Tefferi, A., Abdelmagid, M., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Gangat, N., Orazi, A., Chen, D., Reichard, K. K. & Pardanani, A., Jan 2024, In: American journal of hematology. 99, 1, p. 21-27 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mast-Cell Leukemia 100%
  • Systemic Mastocytosis 86%
  • Survival 32%
  • Hematologic Neoplasms 27%
  • Neoplasms 10%

• Mast cell cytomorphology and treatment outcome in mast cell leukemia

  Tefferi, A., Pardanani, A., Al-Kali, A., Alkhateeb, H., McCullough, K., Patnaik, M., Hogan, W. J., Begna, K., Elliott, M. A., Khera, N., Palmer, J. M., Gangat, N., Kelemen, K., Orazi, A., Chen, D. & Reichard, K. K., Jan 2024, In: American journal of hematology. 99, 1, p. E5-E8

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia

  Gangat, N., McCullough, K., Abdelmagid, M., Karrar, O., Powell, M., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Saliba, A., Torghabeh, M. H., Litzow, M., Hogan, W., Shah, M., Patnaik, M., Pardanani, A., Badar, T., Foran, J., Palmer, J., Sproat, L., & 2 othersYi, C. A. & Tefferi, A., Jan 2024, In: Haematologica. 109, 1, p. 287-292 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• One thousand patients with essential thrombocythemia: the Mayo Clinic experience

  Gangat, N., Karrar, O., Al-Kali, A., Begna, K. H., Elliott, M. A., Wolanskyj-Spinner, A. P., Pardanani, A., Hanson, C. A., Ketterling, R. P. & Tefferi, A., Dec 2024, In: Blood cancer journal. 14, 1, 11.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Essential Thrombocythemia 100%
  • cefotaxime syn S-oxide 80%
  • Survival 41%
  • Thrombosis 38%
  • Abnormal Karyotype 34%

• Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome

  Pardanani, A., Tefferi, A., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Elliott, M. A., Khera, N., Palmer, J. M., Gangat, N., Orazi, A., Kelemen, K., Reichard, K. K. & Chen, D., Jan 2024, In: American journal of hematology. 99, 1, p. E1-E4

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

  Gangat, N., Karrar, O., Iftikhar, M., McCullough, K., Johnson, I. M., Abdelmagid, M., Abdallah, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Saliba, A. N., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., & 6 othersForan, J., Palmer, J., Sproat, L., Khera, N., Arana Yi, C. & Tefferi, A., Feb 2024, In: American journal of hematology. 99, 2, p. 193-202 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Genotype 45%
  • Mutation 35%
  • Survival 34%

• Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

  Karrar, O., Abdelmagid, M., Rana, M., Iftikhar, M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Elliott, M. A., Mangaonkar, A., Saliba, A., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., Foran, J., & 6 othersPalmer, J., Sproat, L., Khera, N., Arana Yi, C., Tefferi, A. & Gangat, N., Feb 2024, In: American journal of hematology. 99, 2, p. E63-E66

  Research output: Contribution to journal › Letter › peer-review

  Open Access
• 2023

  Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  Abdallah, M., McCullough, K., Ilyas, R., Begna, K. H., Al-Kali, A., Litzow, M. R., Hogan, W. J., Mangaonkar, A., Alkhateeb, H., Shah, M. V., Elliott, M. A., Foran, J. M., Badar, T., Palmer, J. M., Yi, C. A., Sproat, L., Pardanani, A., Patnaik, M. M., Olteanu, H., Ketterling, R. P., & 2 othersTefferi, A. & Gangat, N., Dec 2023, In: Blood cancer journal. 13, 1, 35.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival

  Tefferi, A., Singh, A., Gangat, N., Al-Kali, A., Alkhateeb, H., Shah, M., Patnaik, M. S., Elliott, M. A., Hogan, W. J., Litzow, M. R., Wolanskyj-Spinner, A., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Begna, K. H. & Ketterling, R. P., Jan 2023, In: Haematologica. 108, 1, p. 245-249 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression

  Al-Kali, A., Tibes, R., Atherton, P., Palmer, J., Alkhateeb, H. B., Patnaik, M., Begna, K., Gangat, N., Hashmi, S., He, R. & Litzow, M., Mar 2023, In: American journal of hematology. 98, 3, p. 472-480 9 p.

  Research output: Contribution to journal › Article › peer-review

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 100%
  • Daunorubicin 87%
  • Cytarabine 78%
  • Acute Myeloid Leukemia 65%
  • Cell Transplantation 24%

• Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival

  Gangat, N., Kuykendall, A., Ali, N. A., Goel, S., Abdelmagid, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Komrokji, R. & Tefferi, A., Jun 1 2023, In: Blood Advances. 7, 12, p. 2694-2698 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

  Abdelmagid, M. G., Al-Kali, A., Begna, K. H., Hogan, W. J., Litzow, M. R., Fleti, F., Mangaonkar, A. A., Patnaik, M. S., Elliott, M. A., Alkhateeb, H., Shi, M., Howard, M. T., Reichard, K. K., Ketterling, R. P., Shah, M., Pardanani, A., Gangat, N. & Tefferi, A., Sep 2023, In: Haematologica. 108, 9, p. 2542-2545 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: The Mayo Clinic experience

  Katamesh, B., Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Greipp, P., Bessonen, K., Gangat, N., Begna, K., Mangaonkar, A., Patnaik, M., Hogan, W. J., Tefferi, A., Litzow, M., Shah, M. V., Yi, C. A., Foran, J., Badar, T., Alkhateeb, H. B. & Al-Kali, A., Apr 25 2023, In: Blood Advances. 7, 8, p. 1351-1355 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms

  Katamesh, B., Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Greipp, P., Foran, J., Begna, K., Gangat, N., Patnaik, M., Tefferi, A., Litzow, M., Mangaonkar, A., Shah, M. V., Badar, T., Alkhateeb, H. B. & Al-Kali, A., Jan 2023, In: Annals of hematology. 102, 1, p. 211-212 2 p.

  Research output: Contribution to journal › Letter › peer-review

• Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

  Gangat, N., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M., Pardanani, A. & Tefferi, A., Dec 2023, In: Blood cancer journal. 13, 1, 3.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 100%
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 82%
  • Fedratinib 82%
  • INCB018424 66%
  • Primary Myelofibrosis 53%

• Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

  Gangat, N., Ilyas, R., Johnson, I. M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A. & Tefferi, A., Nov 2023, In: Haematologica. 108, 11, p. 3170-3174 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

  Gangat, N., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M., Pardanani, A. & Tefferi, A., Feb 2023, In: American journal of hematology. 98, 2, p. 282-289 8 p.

  Research output: Contribution to journal › Article › peer-review

  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 100%
  • Primary Myelofibrosis 64%
  • Anemia 43%
  • Survival 28%
  • Mutation 17%

• Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm

  Gangat, N., Ilyas, R., McCullough, K., Begna, K. H., Al-Kali, A., Patnaik, M. M., Litzow, M. R., Hogan, W. J., Mangaonkar, A., Alkhateeb, H., Shah, M. V., Elliott, M. A., Foran, J. M., Badar, T., Palmer, J. M., Hanson, C. A., Pardanani, A. & Tefferi, A., May 2023, In: Haematologica. 108, 5, p. 1423-1428 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

  Abdelmagid, M. G., Al-Kali, A., Litzow, M. R., Begna, K. H., Hogan, W. J., Patnaik, M. S., Hashmi, S. K., Elliott, M. A., Alkhateeb, H., Karrar, O. S., Fleti, F., Elnayir, M. H., Rivera, C. E., Murthy, H. S., Foran, J. M., Kharfan-Dabaja, M. A., Badar, T., Viswanatha, D. S., Reichard, K. K., Gangat, N., & 1 othersTefferi, A., Dec 2023, In: Blood cancer journal. 13, 1, 122.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ponatinib 100%
  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 87%
  • Leukemia, Myeloid, Chronic Phase 82%
  • Survival 33%
  • Allografts 11%

• Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases

  Gangat, N., Abdallah, M., Szuber, N., Saliba, A., Alkhateeb, H., Al-Kali, A., Begna, K. H., Pardanani, A. & Tefferi, A., Jul 2023, In: American journal of hematology. 98, 7, p. E165-E167

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Spectrum of clonal hematopoiesis in VEXAS syndrome

  Gutierrez-Rodrigues, F., Kusne, Y., Fernandez, J., Lasho, T., Shalhoub, R., Ma, X., Alessi, H., Finke, C., Koster, M. J., Mangaonkar, A., Warrington, K. J., Begna, K., Xie, Z., Ombrello, A. K., Viswanatha, D., Ferrada, M., Wilson, L., Go, R., Kourelis, T., Reichard, K., & 16 othersOlteanu, H., Darden, I., Hironaka, D., Alemu, L., Kajigaya, S., Rosenzweig, S., Calado, R. T., Groarke, E. M., Kastner, D. L., Calvo, K. R., Wu, C. O., Grayson, P. C., Young, N. S., Beck, D. B., Patel, B. A. & Patnaik, M. M., Jul 20 2023, In: Blood. 142, 3, p. 244-259 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoiesis 100%
  • Vacuoles 97%
  • Myelodysplastic Syndromes 82%
  • Mutation 77%
  • Clone Cells 72%

• The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms

  Gurney, M., Chekkaf, I., Baranwal, A., Basmaci, R., Katamesh, B., Greipp, P., Foran, J. M., Badar, T., Mangaonkar, A. A., Begna, K. H., Gangat, N., Patnaik, M. M., Litzow, M. R., Shah, M. V., Viswanatha, D. S., He, R., Alkhateeb, H. B. & Al-Kali, A., Jul 2023, In: British journal of haematology. 202, 2, p. 279-283 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Mutation 100%
  • Neoplasms 57%
  • Karyotype 52%
  • Primary Myelofibrosis 31%
  • Translational Medical Research 28%

• TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

  Hiwase, D., Hahn, C., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., Sharplin, K., Ladon, D., Hollins, R., Greipp, P., Kutyna, M., Alkhateeb, H., Badar, T., Wang, P., Ross, D. M., Singhal, D., Shanmuganathan, N., Bardy, P., Beligaswatte, A., Yeung, D., & 21 othersLitzow, M. R., Mangaonkar, A., Giri, P., Lee, C., Yong, A., Horvath, N., Singhal, N., Gowda, R., Hogan, W., Gangat, N., Patnaik, M., Begna, K., Tiong, I. S., Wei, A., Kumar, S., Brown, A., Scott, H., Thomas, D., Kok, C. H., Tefferi, A. & Shah, M. V., Mar 2 2023, In: Blood. 141, 9, p. 1087-1091 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases

  Fleti, F., Chan, O., Singh, A., Abdelmagid, M. G., Al-Kali, A., Elliott, M. A., Begna, K. H., Foran, J. M., Badar, T., Khera, N., Al Ali, N. H., Padron, E., Sallman, D. A., Shah, M., Hiwase, D., Pardanani, A., Arber, D. A., Orazi, A., Reichard, K. K., He, R., & 4 othersKetterling, R. P., Gangat, N., Komrokji, R. & Tefferi, A., Apr 2023, In: American journal of hematology. 98, 4, p. E76-E79

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)

  Tefferi, A., Fleti, F., Chan, O., Al Ali, N. H., Al-Kali, A., Begna, K. H., Foran, J. M., Badar, T., Khera, N., Shah, M., Hiwase, D., Padron, E., Sallman, D. A., Pardanani, A., Arber, D. A., Orazi, A., Reichard, K. K., He, R., Ketterling, R. P., Gangat, N., & 1 othersKomrokji, R., 2023, (Accepted/In press) In: British journal of haematology.

  Research output: Contribution to journal › Article › peer-review

  • Myelodysplastic Syndromes 100%
  • Gene Frequency 86%
  • Survival 49%
  • Allogeneic Cells 23%
  • Decision Making 18%
• 2022

  1.5 million platelet count limit at essential thrombocythemia diagnosis: Correlations and relevance to vascular events

  Gangat, N., Szuber, N., Jadoon, Y., Farrukh, F., Begna, K., Elliott, M. A., Wolanskyj-Spinner, A. P., Hanson, C. A., Pardanani, A. D., De Stefano, V., Barbui, T., Vannucchi, A. M. & Tefferi, A., Jul 12 2022, In: Blood Advances. 6, 13, p. 3835-3839 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy

  Tefferi, A., Gangat, N., Al-Kali, A., Alkhateeb, H., Shah, M., Patnaik, M. S., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Ketterling, R. P., DiNardo, C. D., Kadia, T. M., Ravandi, F., Sasaki, K. & Begna, K. H., Sep 2022, In: American journal of hematology. 97, 9, p. 1127-1134 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Induction Chemotherapy 100%
  • Acute Myeloid Leukemia 79%
  • Survival 46%
  • Karyotype 28%
  • Hematopoietic Stem Cells 27%

• AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

  Daver, N., Montesinos, P., Aribi, A., Martinelli, G., Altman, J. K., Wang, E. S., Roboz, G. J., Burke, P. W., Gaidano, G., Walter, R. B., Thomas, X., Jeyakumar, D., DeAngelo, D. J., Erba, H. P., Todisco, E., Begna, K., Advani, A., Gastaud, L., de la Fuente, A., Curti, A., & 19 othersMendez, L. M., Vyas, P., Boissel, N., Vey, N., Recher, C., Longval, T., Platzbecker, U., Kapp-Schwörer, S., Schliemann, C., Konopleva, M., Torres, L., Sallman, D. A., Marcucci, G., Marconi, G., Kantarjian, H., Sloss, C. M., Malcolm, K. E., Zweidler-McKay, P. A. & Sweet, K., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S231-S232

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Azacitidine 83%
  • insulin receptor-related receptor 66%
  • Acute Myeloid Leukemia 60%
  • CR 6 17%

• Autoimmune manifestations in STAG2-mutated myeloid neoplasms

  Katamesh, B., Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Greipp, P., Foran, J., Begna, K., Gangat, N., Patnaik, M., Tefferi, A., Litzow, M., Mangaonkar, A., Shah, M. V., Badar, T., Alkhateeb, H. B. & Al-Kali, A., Dec 2022, In: Annals of hematology. 101, 12, p. 2785-2787 3 p.

  Research output: Contribution to journal › Letter › peer-review

• Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents

  Johnson, I. M., Bezerra, E. D., Farrukh, F., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K., Litzow, M. R., Hogan, W. J., Shah, M. V., Patnaik, M. M., Tefferi, A. & Gangat, N., Sep 13 2022, In: Blood Advances. 6, 17, p. 5227-5231 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

  Abdelmagid, M. G., Litzow, M. R., McCullough, K. B., Gangat, N., Pardanani, A., Murthy, H. S., Foran, J. M., Ketterling, R. P., Viswanatha, D., Begna, K. H. & Tefferi, A., Jul 2022, In: Blood cancer journal. 12, 7, 103.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases

  Tefferi, A., Kittur, J., Farrukh, F., Begna, K. H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Reichard, K. K., Gangat, N. & Pardanani, A., Feb 2022, In: British journal of haematology. 196, 4, p. 975-983 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Systemic Mastocytosis 100%
  • Cladribine 99%
  • Mast-Cell Leukemia 14%
  • Therapeutics 11%
  • Tryptases 11%

• Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

  Begna, K. H., Xu, X., Gangat, N., Alkhateeb, H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Wolanskyj-Spinner, A. P., Mangaonkar, A., He, R., Pardanani, A., Shah, M., Ketterling, R. P. & Tefferi, A., Apr 2022, In: Blood cancer journal. 12, 4, 55.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

  Tefferi, A., Gangat, N., Shah, M., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Ketterling, R. P. & Begna, K. H., Oct 2022, In: Haematologica. 107, 10, p. 2474-2479 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

  Begna, K. H., Kittur, J., Gangat, N., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Pardanani, A., Hanson, C. A., Ketterling, R. P. & Tefferi, A., Jan 2022, In: Blood cancer journal. 12, 1, 7.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoietic Stem Cells 100%
  • Acute Myeloid Leukemia 96%
  • Transplants 63%
  • Survival 31%
  • Karyotype 29%

• Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting

  Singh, A., Al-Kali, A., Foran, J. M., Elliott, M. A., Begna, K., Badar, T., Khera, N., Fleti, F., Abdelmagid, M., Reichard, K. K., Ketterling, R. P., Pardanani, A., Gangat, N. & Tefferi, A., Oct 2022, In: American journal of hematology. 97, 10, p. E377-E379

  Research output: Contribution to journal › Letter › peer-review

• Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience

  Gangat, N., McCullough, K., Al-Kali, A., Begna, K. H., Patnaik, M. M., Litzow, M. R., Hogan, W., Shah, M., Alkhateeb, H., Mangaonkar, A., Foran, J. M., Palmer, J. M., Pardanani, A. & Tefferi, A., Aug 2022, In: British journal of haematology. 198, 4, p. e54-e58

  Research output: Contribution to journal › Letter › peer-review

• Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts

  Gangat, N., Chetram, D., McCullough, K., Al-Kali, A., Begna, K., Hogan, W., Litzow, M., Foran, J., Badar, T., Palmer, J., Patnaik, M., Pardanani, A. & Tefferi, A., Dec 2022, In: American journal of hematology. 97, 12, p. E474-E477

  Research output: Contribution to journal › Letter › peer-review

• Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T

  Mangaonkar, A. A., Farrukh, F., Reichard, K. K., Ketterling, R. P., Gangat, N., Al-Kali, A., Begna, K., Pardanani, A., Patnaik, M. M. & Tefferi, A., Mar 1 2022, In: American journal of hematology. 97, 3, p. E109-E112

  Research output: Contribution to journal › Letter › peer-review

• Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases

  Singh, A., Al-Kali, A., Begna, K. H., Litzow, M. R., Larsen, J. T., Sher, T., Abdelmagid, M. G., Farrukh, F., Reichard, K. K., Gangat, N., Pardanani, A. & Tefferi, A., May 2022, In: American journal of hematology. 97, 5, p. 630-637 8 p.

  Research output: Contribution to journal › Article › peer-review

  • midostaurin 100%
  • Systemic Mastocytosis 88%
  • Mast-Cell Leukemia 17%
  • Cladribine 14%
  • Tryptases 13%

• Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience

  Farrukh, F., Gangat, N., Shah, M. V., Litzow, M. R., Elliott, M. A., Begna, K., Hook, C. C., Tefferi, A. & Pardanani, A., Apr 2022, In: American journal of hematology. 97, 4, p. E138-E140

  Research output: Contribution to journal › Letter › peer-review

• Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients

  He, R., Chiou, J., Chiou, A., Chen, D., Chen, C. P., Spethman, C., Bessonen, K. R., Oliveira, J. L., Nguyen, P. L., Reichard, K. K., Hoyer, J. D., Althoff, S. D., Roh, D. J., Miller, M. A., Yuan, J., Olteanu, H., Begna, K., Tefferi, A., Alkhateeb, H., Patnaik, M. M., & 3 othersLitzow, M. R., Al-Kali, A. & Viswanatha, D. S., Jan 2022, In: Blood cancer journal. 12, 1, 12.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia

  Gangat, N., Johnson, I., McCullough, K., Farrukh, F., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Litzow, M., Hogan, W., Shah, M., Patnaik, M., Pardanani, A. & Tefferi, A., Oct 2022, In: Haematologica. 107, 10, p. 2501-2505 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib

  Tefferi, A., Pardanani, A., Begna, K. H., Al-Kali, A., Hogan, W. J., Litzow, M. R., Hanson, C. A., Ketterling, R. P. & Gangat, N., Dec 2022, In: American journal of hematology. 97, 12, p. E433-E435

  Research output: Contribution to journal › Letter › peer-review

• Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients

  Mangaonkar, A. A., Lasho, T. L., Ketterling, R. P., Reichard, K. K., Gangat, N., Al-Kali, A., Begna, K. H., Pardanani, A., Al Ali, N. H., Talati, C., Sallman, D., Padron, E., Patnaik, M. M., Tefferi, A. & Komrokji, R., Feb 2022, In: Blood cancer journal. 12, 2, 26.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Thrombocytosis 100%
  • Abnormal Karyotype 52%
  • Survival 42%
  • Hemoglobins 30%
  • Refractory Anemia 27%

• Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms

  Shah, M. V., Chhetri, R., Dholakia, R., Kok, C. H., Gangat, N., Alkhateeb, H. B., Al-Kali, A., Patnaik, M. M., Baranwal, A., Greipp, P. T., He, R., Begna, K. H., Tiong, I. S., Wei, A. H. & Hiwase, D., Aug 2022, In: American journal of hematology. 97, 8, p. 1013-1022 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Second Primary Neoplasms 71%
  • Survival 27%
  • Acute Myeloid Leukemia 13%
  • Progression-Free Survival 12%